B

Biohaven Pharmaceuticals

1157 employees

Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.

Investor insights

Sectors invested in

Health Care3
Pharmaceutical2
Medical2
Biotechnology1
Biopharma1
Life Science1

Funding rounds participated in

$20M sweet spot round size

Most of their 3 investments are in rounds between $19M and $21M

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Diagnostics
Neurology
Neuroscience
Health Care
Oncology
Pharmaceutical

Date founded

2014

Investments made

A

Artizan Biosciences, Inc. raised $19M on March 1, 2021

Investors: Elm Street Ventures, Osage University Partners (OUP) and Biohaven Pharmaceuticals

K

Kleo Pharmaceuticals Inc. raised $21M on November 14, 2018

Investors: Biohaven Pharmaceuticals

K

Kleo Pharmaceuticals Inc. raised undisclosed on September 1, 2016

Investors: Biohaven Pharmaceuticals

Funding rounds raised

Total raised

$80M

from 4 investors over 4 rounds

B

Biohaven Pharmaceuticals raised $80M on November 1, 2016

Investors: Osage University Partners (OUP), RA Capital Management, L.P., Vivo Capital and Venrock

FAQ